Treating HCT116 and HT29 with TQ and IR reduced the expression of the stem cell marker CD133 in HT29 but not in HCT116 cells, suggesting that combination treatment may be targeting different CRC stem cell markers in these cells. The gene discussed is PROM1; the disease is colorectal carcinoma.